AI-Based Pathology Diagnostic Tool for Gastric Cancer Achieves 100% Sensitivity in Trials
Posted on 29 Nov 2021
Olympus Life Science (Waltham, MA, USA) has announced the results of its ongoing joint research program to create an AI-based pathology diagnostic tool with the potential to streamline pathologists’ workloads. The diagnostic tool achieved 100% sensitivity and 50% or more specificity for all gastric biopsy pathology specimens analyzed.
The ongoing shortage of pathologists has led to a demand for AI-based pathology diagnostic tools. Olympus, through its Office of Innovation, began developing an AI-based pathology diagnostic tool. In the initial testing phase, the AI was trained using 368 gastric biopsy pathology slide images. The second phase of research began in November 2020, when the diagnostic tool was expanded to six hospitals in Japan, with the aim of verifying the versatility and improving the accuracy of the AI tool. Specifically, it was important to test whether the tool works correctly on pathology slides that vary in thickness and color. The goal of this program is to deliver AI pathology diagnosis software that can assist pathologists by 2023.
The AI-based pathology tool uses a convolutional neural network6 (CNN) optimized to analyze pathology images. This technology enables the tool to identify adenocarcinoma7 versus non-adenocarcinoma tissue in an image. Once the AI was trained, it was tested using 1200 pathology whole slide images from the six institutions participating in the study. The AI classified each image as either adenocarcinoma or non-adenocarcinoma. The AI tool was able to achieve 100% sensitivity and 50% or higher specificity for slides from all six facilities. The robustness of the results will enable Olympus to pursue commercialization of the AI tool in the future.
Related Links:
Olympus Life Science
